Alnylam announces approval of GIVLAARI by US FDA
This article was originally published here
AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of
The post Alnylam announces approval of GIVLAARI by US FDA appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!